Neoadjuvant immune checkpoint inhibition improves protection against hepatic melanoma metastasis
Our data demonstrate that neoadjuvant ICI provides superior protection against hepatic melanoma metastasis with a shift towards an anti-tumor T<sub>H1</sub> immune response. Therefore, neoadjuvant ICI is a promising therapeutic option for CM to prevent the development of organ-specific therapy resistance mechanisms.
Authors
- Tamara Boschert (ORCID: https://orcid.org/0009-0007-8957-5319)
- Cyrill Géraud (ORCID: https://orcid.org/0000-0001-9432-6869)
- Bianca Dietsch
- Verena Häfele
- Sebastian A. Wohlfeil (ORCID: https://orcid.org/0000-0003-4677-6149)
- Christof Dormann
- Céline Weller
- Michael Platten (ORCID: https://orcid.org/0000-0002-4746-887X)
- Dennis A. Agardy (ORCID: https://orcid.org/0000-0001-6900-2504)
- Sergij Goerdt (ORCID: https://orcid.org/0000-0002-5718-415X)
- Niklas Straub
- Sheila A Vormehr
Institutions
- German Cancer Research Center (DE)
- Johannes Gutenberg University Mainz (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- National Center for Tumor Diseases (DE)
- University Medical Centre Mannheim (DE)
Publication Details
- Journal
- Cancer Letters
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1016/j.canlet.2025.217950
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00